Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease

Trial Profile

Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Estradiol/dydrogesterone (Primary) ; Estradiol/dydrogesterone (Primary)
  • Indications Cardiovascular disorders; Venous thromboembolism
  • Focus Pharmacodynamics
  • Acronyms OPTIMISE
  • Sponsors Abbott Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Oct 2015 Accrual to date is 80% according to United Kingdom Clinical Research Network record.
    • 22 Oct 2015 Accrual to date is 78% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top